PSMA-Targeted Radiotherapy Extends Survival

A drug that delivers radioactive isotopes to cells expressing prostate-specific membrane antigen (PSMA) prolonged the lives of men with metastatic castrate-resistant prostate cancer, researchers reported at the 2021 American Society of Clinical Oncology Annual Meeting. If approved, 177Lu-PSMA-617 would be the first targeted radiopharmaceutical available for treating a common solid tumor, and the first therapy directed at PSMA.